Safety of Monoclonal Antibodies in Children Affected by SARS-CoV-2 Infection

Romani, Lorenza; Carducci, Francesca Ippolita Calò; Chiurchiù, Sara; Cursi, Laura; Luca, Maia De; Giuseppe, Martina Di; Krzysztofiak, Andrzej; Lancella, Laura; Vallesi, Leonardo; Corsetti, Tiziana; Campaña, Andrea; Nicastri, Emanuele; Rossi, Paolo; Bernardi, Stefania

doi:10.3390/children9030369

Cited by 13 publications

(11 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Casirivimab–imdevimab, also known as REGEN‐COV, is an anti‐spike mAb that has been authorized for the treatment of high‐risk patients (>12 years of age, >40 kg) with mild‐to‐moderate COVID‐19. 10 Bamlanivimab, named LY‐CoV555, then combined with etesevimab, showed a beneficial effect for accelerating the natural decline of the viral load over time. In December 2021, it was approved by FDA for patients<12 years.…”

Section: Figurementioning

confidence: 99%

“…In December 2021, it was approved by FDA for patients<12 years. 10 Sotrovimab, formerly known as VIR-7831, is an engineered human mAb that neutralizes SARS-CoV-2. 10 There are several data confirming the safety and efficacy in both adults and pediatric population.…”

mentioning

confidence: 99%

“…10 Sotrovimab, formerly known as VIR-7831, is an engineered human mAb that neutralizes SARS-CoV-2. 10 There are several data confirming the safety and efficacy in both adults and pediatric population. 11 We describe a cohort of 63 SARS-CoV-2-infected IEI patients, providing the first case series report on the early employment of anti-SARS-CoV-2 treatments with antiviral drugs and MAbs in these patients (Table S1).…”

mentioning

confidence: 99%

See 2 more Smart Citations

SARS‐CoV‐2 infection and treatment in a cohort of patients with inborn errors of immunity

Conti

Pacillo

Amodio

et al. 2022

Pediatric Allergy Immunology

Self Cite

View full text Add to dashboard Cite

To the Editor, Many authors recently reported the effect of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic on patients affected by Inborn Errors of Immunity (IEI). 1,2 Although mostly experiencing a mild disease and the course of the infection is comparable or even less symptomatic than the general population, young male IEIs patients were more severely affected and more frequently admitted to intensive care unit compared with the age-matched healthy peers. 3 Most viral variants were actually first described in immunocompromised patients. 4,5 Indeed, impaired B and/or T cell function can be responsible for persisting viral shedding often observed in IEI patients with subsequent higher risk of persistent viral replication and mutation within the host. 6 Noteworthily, in the last 2 years Inborn Errors of type I IFN immunity and autoantibodymediated phenocopies of IEIs were identified as responsible for life-threatening COVID-19. These conditions were not considered in the studies about IEIs and SARS-CoV-2 infection. 7,8 Predisposition to increased risk and most severe infection in IEI, despite a lack of clear data in favor of a high risk for progression to severe COVID-19, led the scientific community to recommend the use of early SARS-CoV2-directed treatments to potentially reduce the incidence of long-lasting infection, as well as morbidity and mortality risk. 9Casirivimab-imdevimab, also known as REGEN-COV, is an antispike mAb that has been authorized for the treatment of high-risk patients (>12 years of age, >40 kg) with mild-to-moderate COVID-19. 10 Bamlanivimab, named LY-CoV555, then combined with etesevimab, showed a beneficial effect for accelerating the natural decline of the viral load over time. In December 2021, it was approved by FDA for patients<12 years. 10 Sotrovimab, formerly known as VIR-7831, is an engineered human mAb that neutralizes SARS-CoV-2. 10 There are several data confirming the safety and efficacy in both adults and pediatric population. 11 We describe a cohort of 63 SARS-CoV-2-infected IEI patients, providing the first case series report on the early employment of anti-SARS-CoV-2 treatments with antiviral drugs and MAbs in these patients (Table S1). Thirty-nine patients were younger than 18 years (median age 9.5 years), whereas 24 were adults (median age 33 years). Male-to-female ratio was 1:1. Seven individuals have been

show abstract

Section: Figurementioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

SARS‐CoV‐2 infection and treatment in a cohort of patients with inborn errors of immunity

Conti

Pacillo

Amodio

et al. 2022

Pediatric Allergy Immunology

Self Cite

View full text Add to dashboard Cite

show abstract

“…Neurological symptoms may appear throughout the course of KD, ptosis is very rare, as only 5 cases have been published previously. [2][3][4][5] It seems to be a late complication that appears between the second and fourth week from the onset of symptoms. In none of the cases, ptosis was remitted after immunoglobulins administration.…”

Section: Refusal To Walk and Ptosis As An Atypical Presentation Of Ka...mentioning

confidence: 99%

“…2,3 To the best of our knowledge, there are few data on its use in children less than 12 years old and weighing less than 40 kg. 4 European Medicine Agency (EMA) and Italian Medicine Agency (AIFA) both authorized sotrovimab for treating COVID-19 in adults and adolescents (from 12 years of age and weighing at least 40 kilograms) who do not require supplemental oxygen and who are at increased risk of the disease becoming severe.…”

mentioning

confidence: 99%